XML 97 R49.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 12 Months Ended
Jun. 30, 2021
Apr. 30, 2021
Dec. 31, 2022
Dec. 31, 2021
Loss Contingencies [Line Items]        
Payments in equity, amount $ 10.0      
Common Stock [Member]        
Loss Contingencies [Line Items]        
Number of common stock issued       399,680
Lonza DMSA        
Loss Contingencies [Line Items]        
Percentage of defer payments agreed for completion   50.00%    
Amount recorded with respect to the potential future payments above the initial cash cap   $ 10.0    
Number of common stock issued 399,680      
Public offering price per share $ 25.02      
Sutro Biopharma Inc [Member]        
Loss Contingencies [Line Items]        
Number of common stock issued     167,780  
Upfront Consideration     $ 22.5  
Upfront Consideration in Cash     10.0  
Upfront Consideration in Cash After Agreement Date     5.0  
Option Exercise Price in Cash     75.0  
Additional Milestone Payments in Cash     60.0  
Accrued Commitment     5.0  
Fair Value on Date of Settlement     8.0  
Sutro Biopharma Inc [Member] | Common Stock [Member]        
Loss Contingencies [Line Items]        
Upfront Consideration     $ 7.5